

Subject Index

A

ABL

- kinase 324
 - kinase domain 210
 - oncogene 7
 - proto-oncogene 16
 - transcripts 139
- accelerated phase (AP) 119
- alpha (1) acidic glycoprotein 84
- acquired drug resistance 81
- acquired von Willebrand syndrome (AVWS) 326
- acrocentric chromosome 5
- β -actin 145
- activation loop 77, 81, 85, 86, 154
- acute lymphoid leukemia (ALL) 21, 194, 212, 238
- acute myeloid leukemia (AML) 16, 39, 194, 212
- AML₁(RUNX₁) 43
 - AML-like chemotherapy 137
- acute respiratory distress syndrome 242
- adaphostin 85
- effects 90
- albumin 104
- alemtuzumab 124
- alkylating agents 1, 6
- allogeneic bone marrow transplants 186
- allogeneic hematopoietic stem cell transplantation 116
- allogeneic stem cell transplantation (allo-SCT) 8, 211, 244, 267
- allogeneic transplantation 126
- allograft donor 119
- alloimmunity 197
- allosteric inhibitor 91
- allylamino-17-demethoxygeldanamycin 176

- 17-allylamino-geldanamycin (17-AAG) 91, 210
- amino acid substitutions 154
- AMN107 228
- amplification efficiency 147
- anagrelide 290, 334
- anagrelide-associated cardiomyopathy 336
- androgen therapy 265
- anemia 62, 111, 261, 263
- angioedema 238
- angiogenesis 264
- anilino phenyl ring led 77
- animal model systems 10
- antibody response 188
- anticoagulation 243
- antigen-presenting cell (APC) 187
- antikyhole limpet hemocyanin (KLH) 195
- antimetabolites 1
- antithymocyte globulin 124
- apheresis 139
- APO2 ligand 175
- apoptosis 26
- aquagenic pruritus 285
- arsenic 103
- arsenic trioxide 4, 178, 209
- arterial oxygen saturation 283
- arterial thrombosis 327, 333
- arthritis 262
- asparaginyl hydroxylation 300
- aspirin 287, 289, 326, 333, 334
- ataxia teleangiectasia mutated (ATM) 49
- ATG 124
- ATP-binding cassette (ABC) 203
- ATP-binding loop 77
- ATP-binding site 154
- aurora kinase 176
- autografting 9, 134, 138
- autologous stem cell transplantation (auto-SCT) 133, 137
- immunomodulatory agents 138

- toxicity 138
- autophosphorylation 174, 221
- 5-aza-2-deoxycytidine (decitabine) 168
- 5-azacytidine (5-AZA) 168

B

- Bartter syndrome 299
- basic fibroblast growth factor (bFGF) 258
- basic region leucine zipper (bZIP) 45
- B-cell lymphoma 227
- BCG cell wall skeleton (BCG-CWS) 194
- BCR 226
- gene 2
- BCR-ABL 108, 166
- allele 156
 - blood levels 144
 - control gene ratio 149
 - fusion 220
 - fusion gene 2, 7, 27, 186
 - fusion protein 191
 - genes 15, 38
 - kinase 205
 - kinase inhibitor 76
 - levels 150
 - – detectable 150
 - – undetectable 150
 - 3-log reduction 159
 - mutations, monitoring 158
 - oncogene 38
 - peptide vaccination 210
 - protein 22
 - – pathway 23
 - – transphosphorylation 22
 - quantitation 148
 - rearrangement 21
 - rearrangement, molecular anatomy 20

- sensitivity 150
- transcript 125, 170, 203
- tyrosine kinase 110
- tyrosine kinase inhibitory activity 166
- BCR-PDGFR α 222
- BCR-protein 19
- bevacizumab 209
- blast crisis (BC) 19, 39, 80, 134, 154, 156, 206
- cytogenetics changes 40
- karyotypes 39
- transplants 119
- blast transformation (BT) 38, 60, 70, 212
- blasts 38
- bleeding 62
- bleeding diathesis 326, 334
- blood cell transplant (BCT) 189
- bone marrow (BM) 38
- bone marrow aplasia 111
- bone marrow cell 9
- bone marrow fibrosis 259
- bone marrow histology 330
- bone marrow transplants 189
- bortezomib 95, 177, 209
- breast cancer 1 (BRCA1) gene 49
- Budd-Chiari 304
- busulfan 6, 8, 40, 117, 118, 124, 135, 136, 265, 268

C

- C₁ values 149
- c-abl gene 7
- calmodulin 258
- cancer dormancy 189
- cancer vaccines 189, 191
- Cap region 22
- carcinogenesis 186
- cardiac disease 241
- carmustine 136
- caspase activation 177
- CCAAT/enhancer binding protein α (C/EBP) 45
- CCyR 65
- cDNA 147
- amplification efficiency 147
- cell adhesion 17
- chaper-one protein complex 176
- chaper-one-rich cell lysates (CRCL) 196
- Charcot-Leyden crystals 241
- Chk1 50
- chlorambucil 243
- 2-chlorodeoxyadenosine (2-CdA) 265
- chromosomal abnormalities 42, 153
- chromosome 17, loss 43

- chronic eosinophilic leukemia (CEL) 236, 239
- chronic granulocytic leukemia 204
- chronic idiopathic myelofibrosis (CIMF) 253
- chronic myeloid disorders, semimolecular classification 323
- chronic myeloid leukemia (CML) 1, 37, 133, 144, 187, 241
- autografting 133
- autografting trialists collaboration 137
- BCR-ABL-negative 220
- course of the disease 37
- history 1
- immune therapy 187
- in chronic phase 116
- monitor response 144
- phases 38
- Ph-negative 220
- Ph positive 59
- response to vaccination 171
- chronic myeloproliferative disorders (CMPD) 16, 220
- chronic neutrophilic leukemia (CNL) 21
- Chuvash polycythemia 298, 300
- CIS-3 302
- cisplatin 48
- clonal assays, X-linked 324
- clonal disorder 254
- clonal evolution 67, 69
- clonal myelopoiesis 325
- clonal rearrangements 121
- clonal thrombocytosis 330
- clonality assay 306
- cobalamin 237
- coefficient of variation (CV) 149
- coiled-coil (CC) motif 22, 94
- collagen fibrosis 264
- colony-forming, unit granulocyte/macrophage (CFU-GM) 173
- comparative genomic hybridization (CGH) 42, 255
- complete cytogenetics remission (CCyR) 117
- complete cytogenetics response (CCR) 27, 144, 202
- complete hematologic remission 202
- complete hematologic response (CHR) 104
- control gene 148
- transcript level 150
- C-reactive protein (CRP) 330
- CrkL
- dephosphorylation 80
- phosphorylation 80, 111
- cuvash polycythemia 299
- cyclical neutropenia 197
- cyclin dependent kinase (CDK) 175
- cyclophosphamide 118, 136, 243

- cytarabine (Ara-C) 8, 103, 105, 108, 134, 202, 206, 208
- low-dose 108
- cytochrome b5 reductase deficiency 303
- cytogenetic analysis, bone marrow 152
- cytogenetic response 152, 168
- cytogenetics analysis 144, 152
- cytokines 237
- cytopenias 205
- cytoplasm 94
- cytosine methylation 168
- cytotoxic chemotherapy 265
- cytotoxicity 169
- cytoreductive therapy 334, 336

D

- dacrocytes 263
- danazol 265
- dasatinib 76, 85, 86, 89, 91, 95, 110, 111, 209, 212, 228
- decitabine 169, 208
- delayed-type hypersensitivity (DHT) 172, 195
- deletions 39
- demethylating agents 95
- demethylation 169
- denaturing high performance liquid chromatography (D-HPLC) 158
- dendritic cell (DC) 174
- based vaccines 195
- vaccines 190
- deoxyhemoglobin 303
- dephosphorylation 80
- dexamethasone 263
- DGF motif 79
- disease phenotypes 223
- DNA plasmid standards 147
- amplification efficiency 147
- DNA polymerase 46
- DNA repair 47
- BCR-ABL defects 47
- DNA-dependent protein kinase (DNA-PKcs) 4
- Dok protein 50
- Dok-1 protein 25
- Dok-2 protein 25
- donor gender, patient 121
- donor lymphocyte infusions (DLI) 121, 126, 187, 190, 212
- double-strand breaks (DSBs) 47
- drug leukemogenicity 336

E

ecchymoses 262
 edema 106
 elastase 52
 ELISPOT 195
 – assay 188
 – response 191
 endogenous erythroid colonies (EEC) 305
 eosinophil lysis 244
 eosinophilia 325, 235
 – reactive causes 237
 epidermal growth factor receptor (EGFR) 76
 epo levels 301
 EPOR gene mutations 302
 erythrocytosis 278, 279, 281, 283, 304
 – causes 284
 erythromelalgia 285, 287, 322, 326, 327
 erythropoiesis 263, 299
 erythropoietin (EPO) 265
 erythropoietin-independent colony (EEC) 280
 essential thrombocythemia (ET) 24, 280, 310, 321
 – classification 323
 – hemorrhagic event 328
 – risk stratification 332
 – thrombotic event 328
 etanercept 266
 etoposide 134, 136, 168, 243
 ETV6 226
 ETV6-PDGFRB fusion 228
 European Group for Blood and Marrow Transplantation (EBMT) 133
 – database 136
 – transplant score 126
 expression profiling 51, 52
 extramedullary blastic disease 70
 extramedullary hematopoiesis (EMH) 262, 277, 290

F

F-actin 18, 22, 25, 94
 factor V Leiden mutation 333
 familial thrombocytosis 322
 Fanconi D2 protein (FANCD2) 48
 farnesyl transferase (Ftase) 166, 208
 farnesyl transferase inhibitors (FTI) 92, 108, 109, 167
 fatigue 61
 FGFR1 fusions 224

fibrocystic pulmonary dysplasia 298
 fibronectin 256
 fibrosis 242
 FIP1L1-PDGFR α 222, 235, 236, 240, 241, 245
 FK506 94
 FKBP-12 94
 flavopiridol 5
 FLT 226
 FLT3 226
 fludarabine 124, 268
 fluorescence resonance energy transfer (FRET) 146
 fluorescence in situ hybridization (FISH) 20, 60, 139, 145, 196
 focal adhesion kinase (FAK) 25
 Fop-Fgfr1 fusion protein 226
 forskolin 45
 Fowler's solution 4
 full blood count (FBC) 60
 functional cloning 307

G

G6PD isoenzymes 28
 Gab2 24, 91
 gastrointestinal stromal tumors (GIST) 80
 GAT-1 259
 G-banding 42
 geldanamycin 176
 gene abnormalities 41
 genetic mutations 27
 geranylgeranyl transferase (GGPTases) 166
 Giemsa banding 5
 Gleich's syndrome 238
 glycines 158
 glycoprotein 104
 GM-CSF 196
 graft-versus-host disease (GvHD) 9, 120, 126, 187, 189, 197
 graft-versus-leukemia (GvL) effect 121, 127, 171, 212
 graft-versus-myelofibrosis (GvMy) effect 268
 granulocyte 3, 324
 Gratwohl score 117
 Gray Platelet Syndrome 257
 Grb2 94, 226
 guanidine diphosphate-triphosphate 19
 guanosine 168
 GVAX vaccine 173

H

³H-thymidine 203
 Hasford scores 64, 116
 heat shock protein (HSPs) 172, 210
 heat shock protein 90 (Hsp90) 91
 heat shock protein-peptide complex vaccines (HSPPCs) 195
 hematocrit 281, 282, 289, 312
 hematological diseases 120
 hematopoiesis 106, 261, 262, 278
 hematopoietic cell phosphatase 307
 hematopoietic protein tyrosine phosphatase (HePTP) 255
 heme oxygenase-1 α (HO-1) 178
 hemoglobin 281, 302, 303
 hemoglobin H disease 254
 hemolysis 263
 hemorrhage 87
 hemothoraces 262
 hepatic vein thrombosis 291
 hepatomegaly 261, 286
 hepatotoxicity 205
 herbimycin 10, 176
 herbimycin A 91
 hereditary hemorrhagic telangiectasia 298
 heterogeneous nuclear ribonucleoprotein E₂ (hnRNPE₂) 45
 HIF-1 299, 300
 histone deacetylase (HDACs) 95, 169
 histone deacetylase inhibitors 210
 histone deacetylation 95
 Hodgkin's disease 238
 homoharringtonine (HHT) 170, 208
 homologous recombination (HR) 47
 HSP70-peptide complexes 172
 human papillomavirus (HPV) 187
 hydrogen bonds 154
 hydroxycarbamide 67, 117
 hydroxyurea 6, 8, 40, 103, 138, 208, 213, 243, 265, 290, 304, 332, 334
 hypereosinophilic syndrome (HES) 235
 – lymphoproliferative 237
 – myeloproliferative variant 237
 – T-cell-associated 245
 – WHO criteria 236
 hyperleukocytosis 63
 hypermethylation 168
 hyperuricemia 288, 304
 hypodiploidy 40
 hypokalemic alkalosis 298
 hypomethylating agents 208
 hypoxanthine guanine phosphoribosyl transferase (HPRT) 46, 254
 hypoxia 302, 303
 hypoxia response element (HRE) 299

I

ibuprofen 289
 idarubicin 134
 idiopathic myelofibrosis (IMF) 24, 280, 310
 idiopathic myeloid metaplasia 4
 imatinib 10, 26, 28, 65, 110, 144, 227
 – as first-line therapy 69
 – combinations with other drugs 108
 – dosage 107
 – failure 126
 – in accelerated phase 69
 – inhibition of protein kinases 78
 – mesylate salt 79
 – refractoriness 80
 – resistance 80, 84, 109, 153, 156, 240
 – side effects 106
 – toxicity profile 66
 imatinib mesylate 15, 50, 103, 151, 166, 186, 202, 205
 – definition of failure 207
 – high-dose 207
 – mode of action 205
 – resistance 207
 imatinib-metabolizing enzyme 84
 imidazolequinazoline derivative 290
 immune therapy 186, 210
 immunoglobulin 70
 immunophenotyping 70
 immunophilin 256
 indomethacin 287
 infection 9
 infectious disease 203
 INK₄/ARF 44
 interferon 8, 27, 67, 68, 108, 117, 265
 – post autograft 136
 – pre-auto-SCT 137
 – resistance 104, 134
 – sensitivity 138
 interferon α (IFN- α) 40, 103, 145, 167, 107, 172, 186, 189, 202, 206, 208, 243, 290
 – failure 170
 interferon consensus sequence binding protein 26
 interferon-associated neuropathy 336
 International Blood Marrow Transplant Registry (IBMTR) 67, 117
 IRIS study 65, 105, 117, 153
 IRIS trial 59, 152
 γ -irradiation 48

J

JAK2 224, 225, 226, 280, 305, 307, 324
 – fusions 224, 225
 – gene 256
 – kinase 308, 309
 – mutation 321
 – V617F 280, 284, 288, 309, 311, 312
 – wild-type 311
 juvenile myelomonocytic leukemia (JMML) 222

L

laminin 256
 LAP score 331
 LAQ824 170
 lenalidomide 266
 leptomycin B 94, 209
 leukapheresis 9, 63, 134, 244
 leukocytosis 223, 289, 304, 305
 leukopenia 104
 Lille scoring system 264
 4,5-log response 153
 lonafarnib 92, 109, 166, 167, 208
 loss-of heterozygosity (LOH) 308, 310
 lymphocytes 3
 lymphoid transformation 70
 lymphoma 19
 lysine 158

M

M315I mutation 157
 major breakpoint cluster region 20
 major cytogenetics response (McyR) 137, 144
 major histocompatibility complex (MHC) 187
 malignant melanoma 187, 191
 mammalian target of rapamycin (mTOR) 93
 Mann-Whitney test 147, 148
 measurement reliability 149
 megakaryocytes 257, 260
 megakaryocytic leukemia 257
 megakaryopoiesis 260
 MEK//MAPK activation 175
 melphalan 135, 136, 265
 membrane receptor stimulation 17
 mepolizumab 245

mesylate salt 79
 methemoglobin 303
 methionine 351 81
 microcytosis 286
 minimal residual disease (MRD) 125
 MIP1 α 26
 misincorporation 46
 mitogene-activated protein kinase (MAPK) 85, 92
 – pathway 175
 mitomycin C 48
 mitoxantrone 168
 molecular analysis 152, 153
 molecular refractoriness 84
 molecularly targeted therapy 16
 monitoring response to therapy 144
 monocytosis 224
 monosomy 39
 Mpl-based assay 331
 Mpl-L 254
 mTOR 174
 – inhibitor 210
 multicolor fluorescence in situ hybridization (M-FISH) 42
 mutation analysis 155, 156
 mutation subclones 157
 mutation, P-loop 157, 158
 mutator phenotype 46
 MYC, overexpression 42
 mycophenolic acid (MA) 178
 myeloablation 121
 myeloblastin 206
 myelodysplastic syndrome (MDS) 39, 194, 239, 255, 311
 myelofibrosis 258, 268, 281, 288
 myelofibrotic stroma 256
 myelofibrosis with myeloid metaplasia (MMM) 254
 myeloid metaplasia 262
 myeloid transformation 213
 myeloma 19
 myeloproliferative leukemia retrovirus (MPLV) 279
 myeloproliferative syndromes 5
 myelosuppression 66, 106
 myeloproliferative disorder (MPD) 297
 myocardial infarction 63
 myristoyl 22

N

Na-K-ATPase 46
 National Marrow Donor Program (NMDP) 119
 natural killer (NK) cells 188, 211

neoplasia 103
 neutropenia 66, 111
 – nonleukemia-related 107
 neutrophil dysfunction 254
 nilotinib 76, 85, 89, 91, 95, 109, 110, 209, 212
 nitrogen mustard (HN₂) 5
 N-methylpiperazine 10, 89
 nonhomologous end-joining (NHEJ) pathway 47
 nonreceptor tyrosine kinases (NRTKs) 221
 Noonan syndrome 24
 N-terminal myristoylation site 85
 nuclear export sequence (NES) 177
 nuclear export signal (NES) 17
 nuclear factor –kappaB (NF κ B) 174
 nuclear localization sequences (NLS) 177
 nuclear localization signals (NLS) 17
 nucleotide excision repair (NER) 48
 NUP98/HOXA9 43

O

oblimersen 95
 ocular migraine 285, 287
 ON012380 85, 90, 177, 210
 open reading frame (ORF) upstream (uORF) 45
 organomegaly 288
 osteomyelosclerotic 260
 osteosclerosis 264
 oxygen affinity 302, 303

P

P8p11 myeloproliferative syndrome (EMS) 223
 P-loop mutations 157, 158
 p14^{ARF} 44
 p16^{INK} 44
 p38 activation 92
 pagophagia 289
 papillary thyroid carcinoma 227
 paroxysmal nocturnal hemoglobinuria 254
 patient age 119
 paxillin 25
 PCR
 – assessment 151
 – primers 146
 – real-time 151
 PD173955 86
 PDGFRA 221, 222
 – tyrosine kinase 240
 PDGFRB 223
 – fusion genes 227
 – gene fusions 222
 PDK-1 inhibitor 93
 Pelger-Huet anomaly 254
 peripheral blood (PB) 38, 61
 peripheral blood stem cells (PBSC) 120, 135
 peripheral venous thrombosis 287
 petechiae 262
 P-glycoprotein 207
 pheochromocytoma 303
 Philadelphia (Ph) chromosome 2, 15, 38, 144, 204
 phlebotomy 289, 304, 312, 336
 phosphate binding loop (P-Loop) 81, 86, 157, 205
 – mutations 109
 phosphatidyl inositol-3,4,5 trisphosphate (PIP₃) 93
 phosphoglycerate kinase (PGK) 254
 phospholipase C- γ 1 18
 phosphorylation 22, 80
 phosphorylation of tyrosine 79
 phosphotyrosine 18
 Ph-positive hematopoietic progenitors 25
 PI₃K
 – activation 26
 – inhibitor 93
PI3K/Akt pathway 174
 PIAS 325
 Pig 94
 pipobroman 334
 plasma volume measurement 283
 plasmacytoid DC function 197
 platelet apheresis 336
 platelet count 64
 platelet cyto-reduction 333
 platelet dysfunctions 62
 pleck-strin-homology (PH) 93
 – domain 19
 plethora 286, 301
 pleural effusion 262
 polyadenylation 240
 polyarteritis nodosa 263
 polycythemia vera (PV) 4, 24, 255, 256, 277, 298, 304
 – familial predisposition 307
 PR1 vaccine 173
 prednisolone 266
 pregnancy 291, 337
 pretransplantation therapy 121
 priapism 63
 primary familial and congenital polycythemia (PFCP) 298, 301
 primary inherited polycythemic disorders (PFCP) 299
 progression free survival (PFS) 152
 proliferating cell nuclear antigen (PCNA) 48

proofreading enzymes 155
 proteasome inhibition 176
 protein kinase C (PKC) 76
 protein phosphatase 2A (PP2A) 44
 proteinase 3 (PRO3) 52, 173, 194
 pruritus 288, 289
 Prv-1 expression assay 331
 P-selectin 259
 Pseudo-Gaucher cells 60
 purpura 62
 pyrido[2,3-d] pyrimidine derivatives 86
 pyrimidine ring 168
 pyruvate kinase 303

Q

quality-of life analysis 105
 quantitative real-time PCR (Q-RT/PCR) 52, 146
 quinacrine fluorescence 5

R

R115777 266
 Rad₅₁ 47
 radioactive phosphorus 5
 radioresistant DNA synthesis (RDS) 50
 radiotherapy 267
 Raf 175
 – inhibitor 92
 rapamycin 94, 109, 174, 210
 Ras 166
 – protein 23
 Ras-guanine nucleotide-releasing –protein (GNRP) 24
 reactive oxygen species (ROS) 48
 reactive thrombocytosis (RT) 328
 real time quantitative PCR (RQ-PCR) 125, 144, 146, 151
 receptor tyrosine kinases (RTKs) 221
 red cell distribution with (RDW) 286
 red cell mass 282, 283
 reduced intensity conditioning (RIC) 116, 121
 renal cancer 197
 reticulin fibrosis 331
 retinoblastoma (RB) protein 17
 retinoblastoma susceptibility (RB₁) gene 45
 reverse transcriptase polymerase chain reaction (RT-PCR) 7, 145, 220
 RNA 145
 – degradation 148

- good quality 155
- standards 147
- Roquinimex 138
- Rossmann motif 158
- Rubinstein-Taybi malformation syndrome 51

S

- saturation mutagenesis 89
- SCH55700 245
- sea-blue histiocytes 60
- serine/threonine kinases 76
- serotonin antagonist 290
- serum epo levels 306
- serum erythropoietin 279
- serum ferritin 330
- serum tryptase 237
- SET 44
- SGX-70430 211
- Sheffield schema 264
- SHP-1 301, 325
- side population 203
- Sirinilimus 94
- small interfering RNA (siRNA) 176
- SOCS 325
- Sokal score 64, 116, 213
- sorafenib 175
- splenectomy 244, 262, 266, 267, 291
- splénomegaly 60, 223, 261, 263, 266, 281, 283, 284, 286, 291
- Src-related kinase 166
- staging systems 63
- STAT 51, 308, 324
 - activation 25
 - pathway 24
- STAT3 protein 305
- STAT5 256
 - pathway 39
- stem cell leukemia-lymphoma syndrome (SCLL) 223
- stem cell transplantation (SCT) 171, 202
- steroid 243
- streptococcus hygroscopicus 94
- stroke 63
- suberoylanilide hydroxamic acid (SAHA) 170
- substrate phosphorylation 77
- Sweet syndrome 262
- systemic lupus erythematosus 263

T

- T lymphocytes 324
- T315I mutation 157
- Taq polymerase 155
- TaqMan probe 146
- Tarui disease 298
- T-cell depletion 9
- T-cell lymphomas 238
- T-cell non Hodgkins lymphoma (T-NHL) 224
- T-cell receptor (TCR) 18, 187
- tenascin 256
- tetramer assay 188, 195
- thalassemia 286
- thalidomide 266, 291
- threonine 176
- threonine T315's 81, 90
- thrombocytopenia 4, 60, 104, 107, 111, 256, 260, 261, 266
- thrombocytosis 224, 267, 279, 284, 304, 305, 326
 - asymptomatic 289
 - causes 329
- thrombopoietin (TPO) 259, 306
- thrombosis 242, 286, 327
 - increased 332
- tipifarnib 167, 208
- tissue inhibitors of metalloproteinases (TIMPS) 258
- tissue necrosis factor (TNF) 266
- total body irradiation (TBI) 118, 133
- TP₅₃ 43
- TPO 325
- TRAIL 210
- transcription factor NF- κ B/Rel 25
- transforming growth factor α (TGF- α) 43
- transforming growth factor β (TGF- β) 26
 - synthesis 258
- transplant-related mortality (TRM) 212
- treatment failure 207
- TRIP11-PDGFRB 222
- trisenox 209
- trisomy 39
- trisomy 8 42
- tuberous sclerosis 2 (TSC2) 93
- tumor necrosis factor (TNF) –related apoptosis-inducing ligand (TRAIL) 175
- tumor suppressor gene 52
- tumor suppressor protein 44
- tyrosine 177 94
- tyrosine kinase activity 76, 138, 225, 280
- tyrosine kinase fusion gene 221, 225, 226
- tyrosine phosphatase 23
- tyrphostin 10, 76

V

- V617F, see JAK2, mutation
- vaccination 172, 186
- van der Waals interaction 154
- Vaquez-Osler disease 277
- vascular endothelial growth factor (VEGF) 175, 209, 258
 - plasma level 177
- vasospastic syndromes 287
- vidaza 208
- vincristine 243
- vitronectin 256
- von Hippel Lindau syndrome 298
- von Hippel Lindau tumor suppressor protein (pVHL) 300
- von Willebrand's disease 286, 287
- Von Willebrand factor 148

W

- WBC count 62
- weight loss 61
- Werner syndrome protein (WRN) 48
- Westgard quality control rules 149, 150
- WHO classification 67
- Will Rogers phenomenon 67
- Wilms tumor protein 1 (WT-1) 173, 188, 194, 210
- wortmannin 210

X

- Xeroderma pigmentosum 48

Z

- ZNF198-FGFR1 fusion 228
- zoledronate 178
- ZRCM5 178